Targeting the transforming growth factor-β signalling pathway in metastatic cancer

European Journal of Cancer

Volumn 46, Issue 7, 2010, Pages 1232-1240

  Korpal, Manav ^a   Kang, Yibin ^a,b  

^a PRINCETON UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Cancer; Metastasis; Molecular therapeutics; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; AP 12009; CYTOTOXIC AGENT; DOXORUBICIN; GC 1008; IMMUNOSUPPRESSIVE AGENT; KI 26894; LIGAND; LY 2109761; LY 2157299; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; MONOCLONAL ANTIBODY 2G7; RAPAMYCIN; SD 208; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ABDOMINAL TUMOR; ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ANTISENSE THERAPY; ARTICLE; BONE METASTASIS; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG SAFETY; GLIOMA; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TECHNOLOGY; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTISENSE ELEMENTS (GENETICS); CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950595599     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.040     Document Type: Article

References (87)

1. Massague J. TGF-beta signal transduction. Annu Rev Biochem 67 (1998) 753-791
2. Massague J. TGFbeta in cancer. Cell 134 2 (2008) 215-230
3. Bierie B., and Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6 7 (2006) 506-520
4. Reiss M., and Barcellos-Hoff M.H. Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45 1 (1997) 81-95
5. Shi Y., and Massague J. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
6. Kang Y. Pro-metastasis function of TGFbeta mediated by the Smad pathway. J Cell Biochem 98 6 (2006) 1380-1390
7. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 6958 (2003) 577-584
8. Kang Y., Chen C.R., and Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 11 4 (2003) 915-926
9. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29 2 (2001) 117-129
10. Massague J., Blain S.W., and Lo R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103 2 (2000) 295-309
11. Cui W., Fowlis D.J., Bryson S., et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86 4 (1996) 531-542
12. Pierce Jr. D.F., Gorska A.E., Chytil A., et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA 92 10 (1995) 4254-4258
13. Tang B., Bottinger E.P., Jakowlew S.B., et al. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4 7 (1998) 802-807
14. Lu S.L., Herrington H., Reh D., et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 20 10 (2006) 1331-1342
15. Munoz N.M., Upton M., Rojas A., et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 66 20 (2006) 9837-9844
16. Ijichi H., Chytil A., Gorska A.E., et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20 22 (2006) 3147-3160
17. Guasch G., Schober M., Pasolli H.A., et al. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12 4 (2007) 313-327
18. Forrester E., Chytil A., Bierie B., et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65 6 (2005) 2296-2302
19. Bhowmick N.A., and Moses H.L. Tumor-stroma interactions. Curr Opin Genet Dev 15 1 (2005) 97-101
20. Cheng N., Chytil A., Shyr Y., Joly A., and Moses H.L. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 6 10 (2008) 1521-1533
21. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 6835 (2001) 375-379
22. Bhowmick N.A., Chytil A., Plieth D., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 5659 (2004) 848-851
23. Cheng N., Bhowmick N.A., Chytil A., et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24 32 (2005) 5053-5068
24. Hahn S.A., Seymour A.B., Hoque A.T., et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55 20 (1995) 4670-4675
25. Thiagalingam S., Lengauer C., Leach F.S., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13 3 (1996) 343-346
26. Siegel P.M., and Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3 11 (2003) 807-821
27. Chen C.R., Kang Y., and Massague J. Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 98 3 (2001) 992-999
28. Yang E.Y., and Moses H.L. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111 2 (1990) 731-741
29. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993;92(6):2569-76.
30. Letterio J.J., and Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 16 (1998) 137-161
31. Oft M., Peli J., Rudaz C., et al. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10 19 (1996) 2462-2477
32. Padua D., and Massague J. Roles of TGFb in metastasis. Cell Res 19 (2009) 89-102
33. Bruna A., Darken R.S., Rojo F., et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11 2 (2007) 147-160
34. Arteaga C.L. Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 16 1 (2006) 30-37
35. Muraoka R.S., Koh Y., Roebuck L.R., et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 23 23 (2003) 8691-8703
36. Siegel P.M., Shu W., Cardiff R.D., Muller W.J., and Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100 14 (2003) 8430-8435
37. Deckers M., van Dinther M., Buijs J., et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66 4 (2006) 2202-2209
38. Kang Y., He W., Tulley S., et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102 39 (2005) 13909-13914
39. Korpal M., Yan J., Lu X., et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 15 8 (2009) 960-966
40. Tian F., DaCosta Byfield S., Parks W.T., et al. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63 23 (2003) 8284-8292
41. Yin J.J., Selander K., Chirgwin J.M., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103 2 (1999) 197-206
42. Kang Y., Siegel P.M., Shu W., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 6 (2003) 537-549
43. Padua D., Zhang X.H., Wang Q., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133 (2008) 66-77
44. Pinkas J., and Teicher B.A. TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol 72 5 (2006) 523-529
45. Nam J.S., Suchar A.M., Kang M.J., et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 66 12 (2006) 6327-6335
46. Morris J, Shapiro G, Tan AR, et al. Phase 1/2 study of GC1008: a human anti transforming growth factor-beta (TGFb) monoclonal antibody (MAb) in patients with advanced malignant melanoma or renal cell carcinoma. J Clin Oncol 2008;26 (Abstract#9028).
47. Tan A.R., Alexe G., and Reiss M. Transforming growth factor-b signaling: emerging stem cell target in metastatic breast cancer?. Breast Cancer Res Treat 115 3 (2009) 453-495
48. Kulkarni A.B., Huh C.G., Becker D., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90 2 (1993) 770-774
49. Ruzek M.C., Hawes M., Pratt B., et al. Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 25 2 (2003) 235-257
50. Oft M., Heider K.H., and Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8 23 (1998) 1243-1252
51. Muraoka R.S., Dumont N., Ritter C.A., et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109 12 (2002) 1551-1559
52. Rowland-Goldsmith M.A., Maruyama H., Matsuda K., et al. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Therapy 1 3 (2002) 161-167
53. Yang Y.A., Dukhanina O., Tang B., et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109 12 (2002) 1607-1615
54. Chen C., Wang X.F., and Sun L. Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. J Biol Chem 272 19 (1997) 12862-12867
55. Wang X.F., Lin H.Y., Ng-Eaton E., et al. Expression cloning and characterization of the TGF-beta type III receptor. Cell 67 4 (1991) 797-805
56. Bandyopadhyay A., Zhu Y., Cibull M.L., et al. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res 59 19 (1999) 5041-5046
57. Bandyopadhyay A., Zhu Y., Malik S.N., et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21 22 (2002) 3541-3551
58. Bandyopadhyay A., Lopez-Casillas F., Malik S.N., et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62 16 (2002) 4690-4695
59. Muraoka-Cook R.S., Kurokawa H., Koh Y., et al. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64 24 (2004) 9002-9011
60. Spearman M., Taylor W.R., Greenberg A.H., and Wright J.A. Antisense oligodeoxyribonucleotide inhibition of TGF-beta 1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells. Gene 149 1 (1994) 25-29
61. Wu RS, Kobie JJ, Besselsen DG, et al. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother 2001;50(5):229-40.
62. Hau P., Jachimczak P., Schlingensiepen R., et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17 2 (2007) 201-212
63. Fernandez T., Amoroso S., Sharpe S., et al. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med 195 10 (2002) 1247-1255
64. Wakefield L.M., and Sporn M.B. Suppression of carcinogenesis: a role for TGF-beta and related molecules in prevention of cancer. Immunol Ser 51 (1990) 217-243
65. Schlingensiepen K.H., Fischer-Blass B., Schmaus S., and Ludwig S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 177 (2008) 137-150
66. Bonniaud P., Margetts P.J., Kolb M., et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 171 8 (2005) 889-898
67. Uhl M., Aulwurm S., Wischhusen J., et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64 21 (2004) 7954-7961
68. Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 2006;12(14 Pt 1):4315-30.
69. Ehata S., Hanyu A., Fujime M., et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98 1 (2007) 127-133
70. Yingling J.M., Blanchard K.L., and Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3 12 (2004) 1011-1022
71. Melisi D., Ishiyama S., Sclabas G.M., et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Therapy 7 4 (2008) 829-840
72. Zhang B., Halder S.K., Zhang S., and Datta P.K. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 277 1 (2009) 114-120
73. Calvo-Aller EBJ, Glatt S, Cleverly A, et al. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase. J Clin Oncol 2008;26 (Abstract#14554).
74. Nam J.S., Terabe M., Kang M.J., et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68 10 (2008) 3915-3923
75. Suzuki E., Kim S., Cheung H.K., et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67 5 (2007) 2351-2359
76. Kobie J.J., Wu R.S., Kurt R.A., et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63 8 (2003) 1860-1864
77. Wojtowicz-Praga S., Verma U.N., Wakefield L., et al. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol 19 3 (1996) 169-175
78. Fakhrai H., Mantil J.C., Liu L., et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Therapy 13 12 (2006) 1052-1060
79. Nemunaitis J., Dillman R.O., Schwarzenberger P.O., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24 29 (2006) 4721-4730
80. Gadir N., Jackson D.N., Lee E., and Foster D.A. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin. Oncogene 27 8 (2008) 1055-1062
81. Dalal B.I., Keown P.A., and Greenberg A.H. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143 2 (1993) 381-389
82. Serganova I., Moroz E., Vider J., et al. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J 23 8 (2009) 2662-2672
83. Hjelmeland M.D., Hjelmeland A.B., Sathornsumetee S., et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Therapy 3 6 (2004) 737-745
84. Inman G.J., Nicolas F.J., Callahan J.F., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62 1 (2002) 65-74
85. Zhao B.M., and Hoffmann F.M. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell 17 9 (2006) 3819-3831
86. Pennison M., and Pasche B. Targeting transforming growth factor-b signaling. Curr Opin Oncol 19 6 (2007) 579-585
87. Ananth S., Knebelmann B., Gruning W., et al. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59 9 (1999) 2210-2216